Dapagliflozin Tablet, Film Coated
Product Images NDC 50090-7971

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 50090-7971). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Scatter Plot And Fitted Line Of Change From Baseline In 24-hour Urinary Glucose Amount Versus Dapagliflozin Dose In Healthy Subjects And Subjects With Type 2 Diabetes Mellitus (t2dm) (semi-log Plot) (Dapagliflozin Fig1)

A dose-response scatter plot with fitted lines depicting dapagliflozin dose (mg) on the x-axis and change from baseline (CFB) in 24-hour urinary glucose (g) on the y-axis. It shows observed values and fitted trend lines for healthy subjects and subjects with type 2 diabetes mellitus (T2DM).*

FDA Label Image

Figure 2: Adjusted Mean Change From Baseline Over Time In Hba1c (%) In A 24-week Active-controlled Study Of Dapagliflozin Initial Combination Therapy With Metformin Xr (Dapagliflozin Fig2)

A line graph showing HbA1c (%) adjusted mean change from baseline over 24 study weeks. It compares three groups: Dapagliflozin 10 mg plus Metformin, Dapagliflozin 10 mg alone, and Metformin alone. The graph includes error bars and a side panel showing 24-week Last Observation Carried Forward (LOCF) data with 95% confidence intervals.*

FDA Label Image

Figure 3 (Dapagliflozin Fig3)

A line graph showing adjusted mean changes in HbA1c percentage from baseline over 24 study weeks for two groups: Placebo + Metformin and Dapagliflozin 10 mg + Metformin. The x-axis represents study weeks, and the y-axis shows percentage change in HbA1c. The graph includes error bars and notes on statistical models used for data analysis.*

FDA Label Image

Figure (Dapagliflozin Fig4)

This is a line chart comparing the percentage of patients with an event over months from randomization between Dapagliflozin and placebo groups. The y-axis shows the percentage of patients with an event, ranging from 0% to 7%, and the x-axis shows time in months up to 60. Two lines represent the groups: a solid line for Dapagliflozin and a dashed line for placebo. Patient numbers at risk at various time points are listed below the x-axis for both groups.*

FDA Label Image

Figure (Dapagliflozin Fig5)

A line graph comparing the percentage of patients with an event over time from randomization between Dapagliflozin and placebo groups over approximately 60 months. The x-axis is labeled 'Months from Randomization' and the y-axis 'Patients with event (%)'. The graph shows fewer events in the Dapagliflozin group relative to placebo. Below the graph, numbers of patients at risk at various time points are listed for both groups.*

FDA Label Image

Chemical Structure (Dapagliflozin Str)

Chemical structure of dapagliflozin depicted as a molecular diagram showing its arrangement of atoms and bonds.*

FDA Label Image

Label Image (Lbl500907971)

Label for Dapagliflozin 5 mg film-coated tablets by A-S Medication Solutions. The label indicates an oral tablet form containing 5 mg of dapagliflozin per tablet. Storage instructions specify keeping the product between 68°F to 77°F. The package contains 30 tablets with NDC 50090-7971.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.